Development of novel anti-osteoarthritis drug
Overview
Centre of Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences has established in vivo and in vitro models of osteoarthritis and designed and constructed small molecule drugs to treat osteoarthritis by targeting arginase.
Technical name of innovation
Novel anti-osteoporosis drug
Research completion
2027
Commercialisation opportunities
Product patent
Problem addressed
By screening and modifying natural small molecules, we tried to develop novel anti-osteoporosis drugs, while lower the side effect of the developed drugs.
Innovation
- Using in vitro and in vivo osteoarthritis models, we designed and constructed specific small molecule drugs targeting specific targets, and obtained lead compounds with anti-osteoarthritis effects.
Key impact
- This research is based on specific targets and aims to develop more effective anti-osteoarthritis drugs through specific molecular modification of protein targets.
- Solving the current predicament of having no effective treatment for osteoarthritis
- Enhance the life quality of osteoarthritis pateints
Application
- Postmenopausal or other osteoporosis and osteoporotic fracture healing
As the branch organization of the Chinese Academy of Sciences, Hong Kong Institute of Science & Innovation (HKISI) is the first national research institution in Hong Kong SAR approved by the central government of China. Centre for Regenerative Medicine and Health (CRMH), the subsidiary of HKISI, is supported by the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. CRMH is funded by CAS and the InnoHK program from the Innovation and Technology Commission, Hong Kong SAR government. With its focus on stem cell therapy & genomic editing, developmental biology, and drug discovery, CRMH promotes the globalization of regenerative medicine research and achievements.
Enquiry
